Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) is pleased to announce a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance the discovery and development of Antibody-Drug Conjugates (ADCs) and bispecific antibodies for the treatment of cancer. This collaboration focuses on leveraging contract research expertise while integrating IPA's proprietary B-cell Select™ platform and artificial intelligence-driven discovery capabilities to

The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data

The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO's advanced mRNA-based antigen expression expertise with IPA's in silico and wet-lab antibody discovery capabilities. The collaboration leverages RIBOPRO's expertise in mRNA sequence optimization and LNP-based delivery with IPA's advanced B-cell screening, single-cell analysis, and deep-l

ImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250224016053/en/Kamil Isaev (Photo: Business Wire) Kamil Isaev Joins IPA's Board of Directors IPA is pleased to welcome Dr. Isaev, a seasoned technology leader and venture strategist, to its

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that its application to transfer its securities to the Nasdaq Capital Market has been approved by Nasdaq Listing Qualifications. This transition allows IPA an additional 180-day compliance period, until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share. The Company's common stock will transfer from the Nasdaq Global Market to the Nasdaq Capital Market at the opening of business on February 21, 2025. This move is in accordance with Nasdaq's Listing Rules and maintains IPA's listing while the Company continues execu

IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ:IPA), a leader in AI-driven antibody discovery and development, today announced the successful completion of its previously disclosed USD $8.8 million "at-the-market" equity offering program (the "ATM Program") alongside the full conversion of its outstanding debenture with Yorkville Advisors, significantly enhancing the Company's capital structure. Strategic ATM Offering Raises USD $7.0 Million Utilizing their ATM program, the Company generated approximately USD $7.0 million in gross proceeds. The Company utilized the ATM

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's proprietary LENSai™ platform, an AI-driven system that analyzes evolutionary patterns in biological data, these novel AI-generated sequences have been optimized to maximize therapeutic performance while improving the patient experience. Enhancements are aimed at increased patentability, ex

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. Traditional drug discovery often builds on outdated frameworks, layering new tools onto existing systems and perpetuating inefficiencies. IPA's first-principles approach breaks from this mold by deconstructing challenges to their fundamentals and rebuilding processes from the ground up. This mindset led to the creation of LE

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. "Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. "She has made significant contributions to IPA's success, including the enhancement of IPA's planning and budgeting process. We wish her the very best in her future endeavors." IPA has initiated a CFO succession process and will p

The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data

The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and

Delivers $6.1 Million Q2 Revenue and Announces Strategic Plan to Reshape Biotech and AI-Driven Drug Discovery IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the second quarter ("Q2") of its 2025 fiscal year ("FY25"), which ended October 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "This quarter marks a pivotal chapter for IPA as we unveil our cutting-edge in silico drug discovery tools, designed to revolutionize the landscape of novel therapeutic development. These advanced platforms offer unprecedented insights and precision, aimed

The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2025, on Tuesday, December 10, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these resul

Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENSai IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year ("FY25"), which ended July 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "Our commitment to end-to-end in silico engineering of antibodies for challenging targets has delivered exceptional results. By harnessing our advanced computational capabilities, we've not only accelerated our R&D process, but also significantly red

The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2025, on Monday, September 16, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to d

Achieves Record $24.5 Million Revenue in FY 2024, Showcases Technological Advancements Expands Laboratory Capabilities and Launches Advanced AI Models, Aimed at Strengthening Market Position Launches Commercial LENSai API, Offering Advanced AI-Powered Solutions Across Multiple Markets and Prepares for Further Launch with its Newest Partner, AWS ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), an artificial intelligence (AI)-driven biotherapeutic research and technology company, today announced its financial results for the fiscal year ended April 30, 2024. All numbers are expressed in Canadian dollars unless otherwise noted. "IPA has achieved significant

The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA) today announces the rescheduling of its full year fiscal 2024 financial results and business highlights release. Originally set for July 25, 2024, the new release date is Monday, July 29, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary valuation calculations on goodwill and intangible assets. This extension ensures that the financial data accurately reflects the Company's value and complies with all regulatory requirements. The delay will allow f

The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, will announce its full year fiscal 2024 financial results and business highlights on Thursday, July 25, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on IPA's Investor Relations website at ir.ipatherapeutics.com. A replay will be archived and available for replay following the conference call. Conference Call: Event Title: ImmunoPrecise Reports Financial Results and

IPA reports a fourth consecutive quarter of increased revenue. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its third quarter of the 2024 fiscal year ("FY24"), which ended January 31, 2024. "ImmunoPrecise Antibodies proudly reports a fourth consecutive quarter of record revenue, demonstrating our capability to fulfill the rising needs of both new and existing clients through our comprehensive antibody discovery and development services. These services are designed to effectively reduce the risk, cost, and time associated with advancing safe

H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00

Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

Industrial Alliance Securities downgraded ImmunoPrecise Antibodies from Buy to Hold

SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

SC 13D - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

ImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250224016053/en/Kamil Isaev (Photo: Business Wire) Kamil Isaev Joins IPA's Board of Directors IPA is pleased to welcome Dr. Isaev, a seasoned technology leader and venture strategist, to its

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. "Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. "She has made significant contributions to IPA's success, including the enhancement of IPA's planning and budgeting process. We wish her the very best in her future endeavors." IPA has initiated a CFO succession process and will p

University of Washington's Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, "for protein structure prediction." This accolade highlights the vital role of computational tools and AI in advancing our understanding of protein structures—principles that are central to IPA's

ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor has been serving as Interim CFO since September 19th, 2023, and now transitions into the role on a permanent basis. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. She has a strong background in driving growth, establishing infrastructure, and implementing effective strategies for value creation in d

-BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. -BioStrand's novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities. -This proprietary software provides the integration of electronic health records, enhancing AI-driven drug discovery and development for industry professionals. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and t

Significant throughput of LSA to advance IPA's diversity- and data-driven drug development and to enrich LENSai™. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA® instrument platform from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby significantly increasing the Company's capacity in performing various label-free protein interaction analyses including best-in-c

IPA appoints Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company. APPOINTMENT OF NEW DIRECTORS TO THE BOARD OF DIRECTORS In surveying the new appointees, Dr. James Kuo, Chair of the Board of IPA, highlighted the following: "It is a testament to our Board's reputation for transparency and shareholder eng

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) announced today that Paul Andreola, a member of the Board of Directors of IPA, has resigned, effective immediately, from the Company's Board of Directors for personal reasons unrelated to the Company. "On behalf of the Company and the Board of Directors, I would like to thank Paul for serving on our Board of Directors. His insightful and experienced contributions were highly valued, and we wish Paul all the best in his future endeavours," commented Jennifer Bath, President and Chief Executive Officer and director of the Company. Mr. Andreola commented, "It has been a privilege to serve on the board since 2018.

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that Dr. Yasmina Abdiche, Chief Scientific Officer, will resign effective July 1, 2021, to pursue other opportunities, and that the board of directors has appointed Dr. Ilse Roodink to take over the role of Chief Scientific Officer. Since 2019, Dr. Ilse Roodink has served as Chairwoman of Talem Therapeutics' Scientific Advisory Committee and has been instrumental in leading IPA's SARS-CoV-2 Polytope™ Cocktail program, serving as the Company's COVID-19 Global Project Manager. In her concurrent role as Scientific Director, sh